Blog

Home  /  Activities   /  EUnetHTA Joint Action 3 (2016 - 2020)   /  PTJA06 – “Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL)” final project plan now available.

PTJA06 – “Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL)” final project plan now available.

The final project plan of the assessment on polatuzumab is now available. The final assessment report will be published on 13th February, 2020.

Please access the final project plan at the following link:

PTJA06 Final Project Plan